4,799
Views
1
CrossRef citations to date
0
Altmetric
Report

Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion

, , , , , , , , , , , , , , , , & show all
Article: 2253570 | Received 14 Mar 2023, Accepted 27 Aug 2023, Published online: 08 Sep 2023
 

ABSTRACT

Therapeutic antibodies sometimes elicit anti-drug antibodies (ADAs) that can affect efficacy and safety. Engineered antibodies that contain artificial amino acid sequences are potentially highly immunogenic, but this is currently difficult to predict. Therefore, it is important to efficiently assess immunogenicity during the development of complex antibody-based formats. Here, we present an in vitro peripheral blood mononuclear cell-based assay that can be used to assess immunogenicity potential within 3 days. This method involves examining the frequency and function of interleukin (IL)-2-secreting CD4+ T cells induced by therapeutic antibodies. IL-2-secreting CD4+ T cells seem to be functionally relevant to the immunogenic potential due to their proliferative activity and the expression of several cytokines. The rates of the donors responding to low and high immunogenic proteins, mAb1, and keyhole limpet hemocyanin were 1.3% and 93.5%, respectively. Seven antibodies with known rates of immunogenicity (etanercept, emicizumab, abciximab, romosozumab, blosozumab, humanized anti-human A33 antibody, and bococizumab) induced responses in 1.9%, 3.8%, 6.4%, 10.0%, 29.2%, 43.8%, and 89.5% of donors, respectively. These data are comparable with ADA incidences in clinical settings. Our results show that this assay can contribute to the swift assessment and mechanistic understanding of the immunogenicity of therapeutic antibodies.

Abbreviations

ADAs=

anti-drug antibodies

APCs=

antigen presenting cells

CPD=

cell proliferation dye

DAVID=

Database for Annotation, Visualization, and Integrated Discovery

DEGs=

differentially expressed genes

GO=

Gene Ontology

IL=

interleukin

KLH=

keyhole limpet hemocyanin

PCSK9=

proprotein convertase subtilisin/kexin type 9

PBMC=

peripheral blood mononuclear cell

7AAD=

7-amino-actinomycin D

Acknowledgments

The authors would also like to thank Jacob Davis for his technical editing.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Author contributions

C.K. designed the study; Y.A. and C.K. wrote the manuscript; Y.A., S.M., T.I, S.I., M.Y., A.T., and C.K. executed the cellular assay and analyzed the assay data; Y.A., T.M., H.M., N.Y., and Y.N. executed the RNA-Seq experiment and analyzed the data; Z.S. produced and characterized the antibodies; M.T., S.C., M.M., J.K., H.S., and M.H. supervised the study.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/19420862.2023.2253570.

Additional information

Funding

This study was funded and supported by Chugai Pharmaceutical Co., Ltd.